Radiotherapy in pediatric medulloblastoma: Quality assessment of Pediatric Oncology Group Trial 9031

Raymond Miralbell, T. J. Fitzgerald, Fran Laurie, Sandy Kessel, Arvin Glicksman, Henry S. Friedman, Marcia Urie, James L. Kepner, Tianni Zhou, Zhengjia Chen, Pat Barnes, Larry Kun, Nancy J. Tarbell

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Purpose: To evaluate the potential influence of radiotherapy quality on survival in high-risk pediatric medulloblastoma patients. Methods and Materials: Trial 9031 of the Pediatric Oncology Group (POG) aimed to study the relative benefit of cisplatin and etoposide randomization of high-risk patients with medulloblastoma to preradiotherapy vs. postradiotherapy treatment. Two-hundred and ten patients were treated according to protocol guidelines and were eligible for the present analysis. Treatment volume (whole brain, spine, posterior fossa, and primary tumor bed) and dose prescription deviations were assessed for each patient. An analysis of first site of failure was undertaken. Event-free and overall survival rates were calculated. A log-rank test was used to determine the significance of potential survival differences between patients with and without major deviations in the radiotherapy procedure. Results: Of 160 patients who were fully evaluable for all treatment quality parameters, 91 (57%) had 1 or more major deviations in their treatment schedule. Major deviations by treatment site were brain (26%), spinal (7%), posterior fossa (40%), and primary tumor bed (17%). Major treatment volume or total dose deviations did not significantly influence overall and event-free survival. Conclusions: Despite major treatment deviations in more than half of fully evaluable patients, underdosage or treatment volume misses were not associated with a worse event-free or overall survival.

Original languageEnglish (US)
Pages (from-to)1325-1330
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume64
Issue number5
DOIs
StatePublished - Apr 1 2006

Fingerprint

Medulloblastoma
radiation therapy
Radiotherapy
Pediatrics
deviation
Therapeutics
Disease-Free Survival
brain
Survival
beds
tumors
rank tests
Infratentorial Neoplasms
dosage
spine
Brain
Etoposide
Random Allocation
schedules
Cisplatin

Keywords

  • Medulloblastoma
  • Pediatric Oncology Group
  • Quality assurance
  • Radiotherapy

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Miralbell, R., Fitzgerald, T. J., Laurie, F., Kessel, S., Glicksman, A., Friedman, H. S., ... Tarbell, N. J. (2006). Radiotherapy in pediatric medulloblastoma: Quality assessment of Pediatric Oncology Group Trial 9031. International Journal of Radiation Oncology Biology Physics, 64(5), 1325-1330. https://doi.org/10.1016/j.ijrobp.2005.11.002

Radiotherapy in pediatric medulloblastoma : Quality assessment of Pediatric Oncology Group Trial 9031. / Miralbell, Raymond; Fitzgerald, T. J.; Laurie, Fran; Kessel, Sandy; Glicksman, Arvin; Friedman, Henry S.; Urie, Marcia; Kepner, James L.; Zhou, Tianni; Chen, Zhengjia; Barnes, Pat; Kun, Larry; Tarbell, Nancy J.

In: International Journal of Radiation Oncology Biology Physics, Vol. 64, No. 5, 01.04.2006, p. 1325-1330.

Research output: Contribution to journalArticle

Miralbell, R, Fitzgerald, TJ, Laurie, F, Kessel, S, Glicksman, A, Friedman, HS, Urie, M, Kepner, JL, Zhou, T, Chen, Z, Barnes, P, Kun, L & Tarbell, NJ 2006, 'Radiotherapy in pediatric medulloblastoma: Quality assessment of Pediatric Oncology Group Trial 9031', International Journal of Radiation Oncology Biology Physics, vol. 64, no. 5, pp. 1325-1330. https://doi.org/10.1016/j.ijrobp.2005.11.002
Miralbell, Raymond ; Fitzgerald, T. J. ; Laurie, Fran ; Kessel, Sandy ; Glicksman, Arvin ; Friedman, Henry S. ; Urie, Marcia ; Kepner, James L. ; Zhou, Tianni ; Chen, Zhengjia ; Barnes, Pat ; Kun, Larry ; Tarbell, Nancy J. / Radiotherapy in pediatric medulloblastoma : Quality assessment of Pediatric Oncology Group Trial 9031. In: International Journal of Radiation Oncology Biology Physics. 2006 ; Vol. 64, No. 5. pp. 1325-1330.
@article{9a7f2dcb819548169e9bb183dfda3184,
title = "Radiotherapy in pediatric medulloblastoma: Quality assessment of Pediatric Oncology Group Trial 9031",
abstract = "Purpose: To evaluate the potential influence of radiotherapy quality on survival in high-risk pediatric medulloblastoma patients. Methods and Materials: Trial 9031 of the Pediatric Oncology Group (POG) aimed to study the relative benefit of cisplatin and etoposide randomization of high-risk patients with medulloblastoma to preradiotherapy vs. postradiotherapy treatment. Two-hundred and ten patients were treated according to protocol guidelines and were eligible for the present analysis. Treatment volume (whole brain, spine, posterior fossa, and primary tumor bed) and dose prescription deviations were assessed for each patient. An analysis of first site of failure was undertaken. Event-free and overall survival rates were calculated. A log-rank test was used to determine the significance of potential survival differences between patients with and without major deviations in the radiotherapy procedure. Results: Of 160 patients who were fully evaluable for all treatment quality parameters, 91 (57{\%}) had 1 or more major deviations in their treatment schedule. Major deviations by treatment site were brain (26{\%}), spinal (7{\%}), posterior fossa (40{\%}), and primary tumor bed (17{\%}). Major treatment volume or total dose deviations did not significantly influence overall and event-free survival. Conclusions: Despite major treatment deviations in more than half of fully evaluable patients, underdosage or treatment volume misses were not associated with a worse event-free or overall survival.",
keywords = "Medulloblastoma, Pediatric Oncology Group, Quality assurance, Radiotherapy",
author = "Raymond Miralbell and Fitzgerald, {T. J.} and Fran Laurie and Sandy Kessel and Arvin Glicksman and Friedman, {Henry S.} and Marcia Urie and Kepner, {James L.} and Tianni Zhou and Zhengjia Chen and Pat Barnes and Larry Kun and Tarbell, {Nancy J.}",
year = "2006",
month = "4",
day = "1",
doi = "10.1016/j.ijrobp.2005.11.002",
language = "English (US)",
volume = "64",
pages = "1325--1330",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Radiotherapy in pediatric medulloblastoma

T2 - Quality assessment of Pediatric Oncology Group Trial 9031

AU - Miralbell, Raymond

AU - Fitzgerald, T. J.

AU - Laurie, Fran

AU - Kessel, Sandy

AU - Glicksman, Arvin

AU - Friedman, Henry S.

AU - Urie, Marcia

AU - Kepner, James L.

AU - Zhou, Tianni

AU - Chen, Zhengjia

AU - Barnes, Pat

AU - Kun, Larry

AU - Tarbell, Nancy J.

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Purpose: To evaluate the potential influence of radiotherapy quality on survival in high-risk pediatric medulloblastoma patients. Methods and Materials: Trial 9031 of the Pediatric Oncology Group (POG) aimed to study the relative benefit of cisplatin and etoposide randomization of high-risk patients with medulloblastoma to preradiotherapy vs. postradiotherapy treatment. Two-hundred and ten patients were treated according to protocol guidelines and were eligible for the present analysis. Treatment volume (whole brain, spine, posterior fossa, and primary tumor bed) and dose prescription deviations were assessed for each patient. An analysis of first site of failure was undertaken. Event-free and overall survival rates were calculated. A log-rank test was used to determine the significance of potential survival differences between patients with and without major deviations in the radiotherapy procedure. Results: Of 160 patients who were fully evaluable for all treatment quality parameters, 91 (57%) had 1 or more major deviations in their treatment schedule. Major deviations by treatment site were brain (26%), spinal (7%), posterior fossa (40%), and primary tumor bed (17%). Major treatment volume or total dose deviations did not significantly influence overall and event-free survival. Conclusions: Despite major treatment deviations in more than half of fully evaluable patients, underdosage or treatment volume misses were not associated with a worse event-free or overall survival.

AB - Purpose: To evaluate the potential influence of radiotherapy quality on survival in high-risk pediatric medulloblastoma patients. Methods and Materials: Trial 9031 of the Pediatric Oncology Group (POG) aimed to study the relative benefit of cisplatin and etoposide randomization of high-risk patients with medulloblastoma to preradiotherapy vs. postradiotherapy treatment. Two-hundred and ten patients were treated according to protocol guidelines and were eligible for the present analysis. Treatment volume (whole brain, spine, posterior fossa, and primary tumor bed) and dose prescription deviations were assessed for each patient. An analysis of first site of failure was undertaken. Event-free and overall survival rates were calculated. A log-rank test was used to determine the significance of potential survival differences between patients with and without major deviations in the radiotherapy procedure. Results: Of 160 patients who were fully evaluable for all treatment quality parameters, 91 (57%) had 1 or more major deviations in their treatment schedule. Major deviations by treatment site were brain (26%), spinal (7%), posterior fossa (40%), and primary tumor bed (17%). Major treatment volume or total dose deviations did not significantly influence overall and event-free survival. Conclusions: Despite major treatment deviations in more than half of fully evaluable patients, underdosage or treatment volume misses were not associated with a worse event-free or overall survival.

KW - Medulloblastoma

KW - Pediatric Oncology Group

KW - Quality assurance

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=33645329333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645329333&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2005.11.002

DO - 10.1016/j.ijrobp.2005.11.002

M3 - Article

C2 - 16413699

AN - SCOPUS:33645329333

VL - 64

SP - 1325

EP - 1330

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -